Prestige BioPharma Limited (950210.KS)
KRW 15050.0
(-4.57%)
KRW 15050.0
(-4.57%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 689.07 Million | 161.84 Million | - | - | - | 2.08 Billion |
| Cost of Revenue | - | 11.65 Billion | 3.86 Billion | 1.66 Billion | 1.18 Billion | 755.33 Million |
| Gross Profit | 689.07 Million | -11.49 Billion | -3.86 Billion | -1.66 Billion | -1.18 Billion | 1.33 Billion |
| Operating Expenses | 63.47 Billion | -905.39 Million | 58.51 Billion | 18.38 Billion | 10.87 Billion | 5.73 Billion |
| Selling, General and Administrative Expenses | 29.89 Billion | 39.59 Billion | 42.84 Billion | 9.31 Billion | 6.2 Billion | 3.41 Billion |
| Research and Development Expenses | - | 40.91 Billion | 17.7 Billion | 10.13 Billion | 4.19 Billion | 2.32 Billion |
| Other Expenses | 33.57 Billion | 73.47 Billion | 15.67 Billion | 9.07 Billion | 4.66 Billion | - |
| Cost and Expenses | 63.47 Billion | -905.39 Million | 58.51 Billion | 18.38 Billion | 10.87 Billion | 6.49 Billion |
| Operating Income | -62.78 Billion | -69.57 Billion | -58.51 Billion | -18.38 Billion | -10.87 Billion | -4.4 Billion |
| Interest Expense | 7.4 Billion | 950.79 Million | 18.85 Million | 6.19 Million | - | - |
| Income Tax Expense | 408.67 Million | 763.27 Million | 800.66 Million | 34.07 Million | 98.47 Million | 187.34 Million |
| Earnings before Tax | -54.68 Billion | -2.09 Billion | -210.64 Billion | -7.35 Billion | -14.89 Billion | -1.26 Billion |
| Net Income | -32.92 Billion | 17.56 Billion | -211.45 Billion | -7.39 Billion | -14.99 Billion | -1.44 Billion |
| Earnings Per Share Basic | -547.81 | 292.35 | -3518.53 | -135.99 | -49.91 | -4.82 |
| Earnings Per Share Diluted | -547.81 | 292.35 | -3518.53 | -135.99 | -49.91 | -4.82 |
| Weighted Average Shares Outstanding | 60.09 Million | 60.09 Million | 60.09 Million | 54.34 Million | 300.48 Million | 300.48 Million |
| Weighted Average Shares Outstanding (Diluted) | 60.09 Million | 60.09 Million | 60.09 Million | 54.34 Million | 300.48 Million | 300.48 Million |
| Gross Margin | 1.00 | -71.04 | - | - | - | 0.64 |
| EBIT Margin | -45.06 | 154.94 | - | - | - | -1.83 |
| Profit Margin | -47.78 | 108.56 | - | - | - | -0.69 |
| EBITDA | -31.04 Billion | 10.51 Billion | -206.9 Billion | -5.68 Billion | -13.71 Billion | -686.46 Million |
| Earnings Before Tax Margin | -91.11 | -429.88 | - | - | - | -2.11 |
| Breakdown | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Revenue | -137.09 Million | 643.02 Million | 119.89 Million | 67.32 Million | 161.84 Million | 161.05 Million |
| Cost of Revenue | - | 4.47 Billion | 3.84 Billion | 3.41 Billion | 11.65 Billion | 3.41 Billion |
| Gross Profit | -137.09 Million | -3.83 Billion | -3.72 Billion | -3.34 Billion | -11.49 Billion | -3.25 Billion |
| Operating Expenses | 9.57 Billion | 13.02 Billion | 15.3 Billion | 17.24 Billion | -905.39 Million | -49.59 Billion |
| Selling, General and Administrative Expenses | -23.96 Billion | 5.25 Billion | 3.39 Billion | 17.24 Billion | - | -9.08 Billion |
| Research and Development Expenses | - | 7.76 Billion | 11.9 Billion | 8.13 Billion | - | 11.15 Billion |
| Other Expenses | -286.53 Million | 316.96 Million | - | 903.12 Million | 73.47 Billion | 18.68 Billion |
| Cost and Expenses | 9.57 Billion | 17.5 Billion | 19.14 Billion | 17.24 Billion | -905.39 Million | -49.59 Billion |
| Operating Income | -9.74 Billion | -16.85 Billion | -19.02 Billion | -17.17 Billion | -69.57 Billion | -20.88 Billion |
| Interest Expense | - | 2.48 Billion | - | 1.83 Billion | 950.79 Million | 9.63 Billion |
| Income Tax Expense | 157.14 Million | 145.25 Million | -33.49 Million | 139.75 Million | 763.27 Million | 128.84 Million |
| Earnings before Tax | -12.89 Billion | -13.24 Billion | -11.64 Billion | -16.89 Billion | -2.09 Billion | -15.2 Billion |
| Net Income | -9.28 Billion | -1.44 Billion | -13.02 Billion | -9.12 Billion | 17.56 Billion | -8.8 Billion |
| Earnings Per Share Basic | -154.51 | -24.09 | -216.79 | -151.80 | - | -146.55 |
| Earnings Per Share Diluted | -154.51 | -24.09 | -216.79 | -151.80 | - | -146.55 |
| Weighted Average Shares Outstanding | 60.09 Million | 60.09 Million | 60.09 Million | 60.09 Million | 60.09 Million | 60.09 Million |
| Weighted Average Shares Outstanding (Diluted) | 60.09 Million | 60.09 Million | 60.09 Million | 60.09 Million | 60.09 Million | 60.09 Million |
| Gross Margin | 1.00 | -5.97 | -31.04 | -49.72 | -71.04 | -20.21 |
| EBIT Margin | -41.97 | -19.25 | -126.63 | -223.64 | - | 295.19 |
| Profit Margin | 67.73 | -2.25 | -108.66 | -135.50 | 108.56 | -54.68 |
| EBITDA | 5.75 Billion | -12.37 Billion | -15.18 Billion | -15.05 Billion | - | 47.54 Billion |
| Earnings Before Tax Margin | 71.08 | -26.22 | -158.67 | -255.12 | -429.88 | -129.68 |
WYGPF
TEMPF
LUDN
LIFFF
300420
DNNGY